Abstract: A cellular medicine transfer system includes: an adapter for a cellular medicine container including a first flow channel and a second flow channel through each of which a liquid and cells can flow; a cellular medicine container to which the adapter is attached, and in which a cellular medicine to be transferred is stored; an administration medium storage container that communicates with the first flow channel, and in which an administration medium is stored; a collection container for collecting a cellular medicine, that communicates with the second flow channel of the adapter; and a powering device that imparts motive power for transferring the administration medium from the administration medium storage container through the first flow channel to the cellular medicine container, and for transferring the cellular medicine and the administration medium from the cellular medicine container through the second flow channel to the collection container.

Abstract: This present disclosure provides reliable methods and apparatus for delivering a pharmaceutical active ingredient to a substrate. In some examples, the pharmaceutical active ingredient is applied to the substrate after the substrate has been fully prepared. The substrate can be an edible product or an inedible substrate. The edible product can be a baked or otherwise cooked good. In some examples, the edible product can be fruits and/or nuts. The method and apparatus for delivering the pharmaceutical agent can be configured to deliver microquantities of the pharmaceutical active ingredient to the substrate.

Abstract: An enteral feeding pump is provided for mounting a tubing set. The enteral feeding pump comprises a base having an outer side. A rotor is supported on the outer side of the base for engaging a tube section of a tubing set. A tubing set platform is provided on the outer side of the base and defines a pair of tube retainer locks. At least one tube retainer lock comprises an elongated channel for receiving a tube retainer defined by a retainer body and a pair of laterally opposing retainer tabs, tab rest surfaces located on laterally opposing sides of the channel, and tab retention surfaces spaced from the tab rest surfaces and defining elongated slots extending in a longitudinal direction parallel to the elongated channel. The elongated slots each include an entrance end for receiving a retainer tab and a longitudinally opposing inner end.

Abstract: The present invention teaches an apparatus that is simultaneously useful for both teething and suckling. The apparatus includes an article of manufacture including a teething section and a section that simulates a nipple for suckling. The invention takes into account the natural position of the infant's thumb during suckling. In addition, the invention teaches regulating the amount of saliva resting on the teething and sucking apparatus surface. Further still, the invention teaches using an elongated strap to secure the teething and sucking apparatus to the infant's wrist to prevent losing it.

Abstract: The present disclosure relates to a combination, a composite staining kit and a method for revealing a composite material on a tooth.

Abstract: A polymerizable monomer, a filler (A), and a filler (B) are contained, the filler (A) includes an inorganic particle and a compound covering the inorganic particle, the filler (B) includes another inorganic particle and another compound covering the other inorganic particle, and the average particle size of the filler (B) is 20% to 550% of the average particle size of the filler (A).

Abstract: The present invention relates to a dental material comprising a thermoset methacrylate-based polymer resin and cellulose nanocrystals, wherein the cellulose nanocrystals have been modified to be hydrophobic.

Abstract: Described herein are oral care compositions comprising metal silicates (e.g. potassium silicate); along with methods of making and using same.

Abstract: The present invention relates to a composition in form of an oil-in-water emulsion comprising: a) a dispersed fatty phase comprising at least one oil chosen from silicone oils, hydrocarbonated oils, or a mixture thereof; b) a continuous aqueous phase comprising at least one C1-C4 alcohol, linear or branched, saturated or unsaturated, mono-, bi-, or tri-, in an amount ranging from 0.1% to 20% by weight, relative to the total weight of the composition; and c) at least one hydrophobic particle chosen from hydrophobic silicas, starch, talc, silicone resin powders, hollow hemispherical silicone particles, polyamide powders, hydrophobic pigments, or a mixture thereof; and d) at least one polysaccharide selected from xanthan gum and gellan gum.

Abstract: Described herein are oral care compositions comprising metal silicates (e.g. sodium silicate); along with methods of making and using same.

Abstract: The present invention relates generally to methods for protecting human skin against light damage and, more specifically, to the use lutein and/or zeaxanthin to protect human skin from damage by exposure to blue light and white light. Another aspect of the present invention relates to methods for repairing damaged skin cells, including mitigating the damage caused by exposure to light or other stressors.

Abstract: This invention relates to syndet-based compositions having pH of 4.5 to 5.5 wherein use of caprylic acid has been unexpectedly found to enhance bacterial kill.

Abstract: Present invention relates to a process for permanent waving keratin fibers, especially human hair, for achieving durable waves wherein fibers are treated with a reducing composition, a non-reducing and non-oxidizing alkaline composition and finally an oxidizing composition wherein after processing the reducing composition the fibers are rinsed off.

Abstract: Disclosed are water-based personal cleansing compositions having an isotropic surfactant phase, the compositions containing (a) an amidoamine surfactant, (b) cleansing surfactant, (c) water, and (d) protonating agent, the cleansing surfactant containing 85 to 100% by weight of a combination of betaine surfactant and taurate surfactant in particular ratios; also disclosed are methods of thickening such compositions by the addition of electrolyte.

Abstract: The present invention relates to a composition for prevention or treatment of hair loss. The composition is effectively delivered into hair papilla cells in a hair loss area, which is a target area, wherein a cytokine or enzyme highly expressed in the hair loss area causes a drug to be separated from a compound contained in the composition so that the drug effectively exhibits activity, which ultimately promotes hair growth and/or hair regrowth.

Abstract: The described invention provides cosmetic formulation stabilizing systems comprising an arginine component and organic acid component, for preserving cosmetic formulations, stable cosmetic and dermatologic formulations comprising the cosmetic formulation stabilizing system, methods for manufacturing the same, and the use of such compositions for skin care.

Abstract: The present invention relates to cochleates using phosphatidylserine/anionic surfactant/calcium chloride and, more specifically, to cochleates comprising phosphatidylserine, an anionic surfactant, calcium chloride, an active ingredient, and water.

Abstract: The present specification discloses a composition for preventing or improving intrinsic aging comprising, as an active ingredient, any one of paeoniflorin or a salt, isomer, hydrate or solvate thereof; and albiflorin or a salt, isomer, hydrate or solvate thereof. Intrinsic aging is one of the natural phenomena occurring with aging, unlike photoaging caused by UV, which is a type of extrinsic aging. The paeoniflorin or albiflorin of the present disclosure is useful for those who want to delay aging and maintain beauty. Accordingly, the paeoniflorin or a salt, isomer, hydrate or solvate thereof; and the albiflorin or a salt, isomer, hydrate or solvate thereof of the present disclosure have the advantage of being capable of being utilized in various forms such as cosmetics, functional health foods, etc.

Abstract: Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.

Abstract: The present invention relates to a composition, in particular comprising a physiologically acceptable medium, in particular for coating keratin materials, more particularly for caring for and/or making up keratin materials, which is a cosmetic composition for making up and/or caring for keratin materials, in particular the skin and/or the lips, comprising: a) cellulose particles; and b) boron nitride particles; and c) nacre particles having a mean size of less than 20.0 ?m. The invention also relates to a process for cosmetic treatment of keratin materials, more particularly for caring for and/or making up keratin materials, such as the skin, characterized in that it comprises the application to the keratin materials of a composition as defined previously.

Abstract: The invention provides a cosmetic base having an unprecedented appearance and feeling on use, in particular a cosmetic base with a novel feeling on use that gives a fresh feeling and a unique feel as the cosmetic softly bursts and collapses, allowing water to flow out, when applied to the skin, and a skin cosmetic using the same. A cosmetic base includes (A) 0.15-0.6 mass % of sodium acrylate-grafted starch and (B) 0.25-1.35 mass % of an associative thickener having a polyoxyalkylene chain wherein the total amount of the (A) sodium acrylate-grafted starch and (B) associative thickener having a polyoxyalkylene chain compounded is 0.5-1.5 mass % and to a skin cosmetic that uses the cosmetic base.

Abstract: A composition suitable for application as a nail polish, the composition comprising: an alcohol solvent; ethylcellulose, in an amount that is about 1.0% by weight of the final composition; a film forming agent that includes maleic acid monobutyl ester-vinyl methyl ether copolymer, and maleic acid monoethyl ester-vinyl methyl ether copolymer, in an amount that is at least 40% by weight of the final composition; isostearyl alcohol, in an amount that is about 3.0% by weight of the final composition; a plasticizer in the form of a citric acid ester, in art amount that is about 1.0% by weight of the final composition; a colorant and a fragrance. This composition is suitable for application to a human nail.

Abstract: The invention relates to the use of a polyurethane urea on hair for improving the water resistance of the hairstyle obtained by shaping the hair, which polyurethane urea is obtained by reacting at least a) a polyisocyanate component, b) a polymer polyol component, c) a hydrophilic component, and d) an amino functional chain extender component, wherein the polyisocyanate component comprises a) ?75% mol-% isophorone diamine (IPDI) and the amino functional chain extender component comprises c) ?75 mol-% isophorone diamine (IPDA).

Abstract: Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.

Abstract: Cannabidiol (CBD) is one of the most abundant and physiologically active phytocannabinoids in Cannabis plants. The chemical has well-known mechanisms that have been the potential to treat and prevent numerous inflammatory, immunologic, anti-infectious, sun-damaged, age-related (wrinkling, drying, hair loss), and neurogenic-related (anti-pain, anti-itch) diseases as well as heal traumatized skin. The incorporation of CBD on or within topically applied formulations or within wound care dressings, biomaterials skin substitutes, or skin adhesives is a novel approach to alleviate, prevent and cure acute and chronic skin disease, and promote normal healing and recovery after injury.

Abstract: A method for manufacturing a preparation for injection, including a first step of performing at least one treatment selected from the group consisting of a treatment of mixing benzyl benzoate with an antioxidant, a treatment of heating benzyl benzoate, and a treatment of purifying benzyl benzoate and a second step of mixing the benzyl benzoate treated by the first step with fulvestrant.

Abstract: The present invention relates to methods of treating blepharitis and dry eye by inhibiting the binding ability of lid flora bacteria such as Staphylococcus aureus and Staphylococcus epidermidis, thus inhibiting biofilm formation and the increase in bacterial populations and densities that lead to quorum-sensing-gene activation and therefore, the production of inflammatory virulence factors.

Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.

Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.

Abstract: A dental tool is provided which is capable of delivering an oligosaccharide containing composition to an oral biofilm, which can prevent and inhibit periodontal disease and in particular to devices and methods which mechanically and chemically disrupt biofilms formed by S. mutans.

Abstract: Disclosed herein are compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed compositions can comprise a flavoring agent and polyethylene glycol. The disclosed compositions are superior to prior art compositions in that the disclosed compositions allow for higher tolerability, lower volumes, and improved patient compliance. In some embodiments, the composition comprises non-fermentable carbohydrates. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.

Abstract: Drug-delivery systems are described which can serve as platforms for topical delivery of a variety of active pharmaceutical ingredients (API) to the surface of a mammalian body. Methods for the preparation and use of the compositions are also described. In some embodiments, the disclosed topical formulations include an API, a penetration enhancer/cosolvent, a gelling agent, and a neutralizing agent (to adjust pH). As compared to prior compositions, the disclosed topical formulations use a relatively small number of safe components and are easy to prepare with a high yield of finished product.

Abstract: This invention concerns a series of excipients capable of effectively reducing the viscosity of protein formulations. The viscosity reducing excipients are oligopeptides (e.g., dipeptides, tripeptides) comprising at least one arginine. The peptides may also include basic or acidic or hydrophilic or hydrophobic/aromatic amino acids. An arginine residue may be either at the amino or the carboxyl end of the oligopeptide.

Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Abstract: The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.

Abstract: The invention relates to a process for the preparation of dry lyophilized powdered formulations of probiotic bacteria for monogastric animal (for example poultry birds) using a combination of different polymers through the process of encapsulation. The resulting lyophilized powders of probiotic bacteria are having increased viability during animal feed processing, storage and upon transfer to the monogastric animal's digestive system.

Abstract: Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.

Abstract: Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.

Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.

Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Abstract: Systems and methods for fabricating ingestible pharmaceutical tablets are provided. Certain of the systems and methods described herein are capable of manufacturing tablets of different dosages without the need to fluidically connect or disconnect unit operations when switching from a tablet having a first dosage to a tablet having a second, different dosage. Certain of the systems and methods described herein are capable of manufacturing compositionally tablets, e.g., tablets with different active pharmaceutical ingredients (APIs).

Abstract: The present invention relates to a new delivery system for nutritional ingredients (nutraceuticals). These nutritional ingredients are useful for gut and metabolic health in monogastric animals, especially in humans.

Abstract: The present disclosure provides a sustained release formulation of opioid receptor antagonists comprising a sustained release granule comprising at least one of the opioid receptor antagonist, at least one of pharmaceutical acceptable carrier, and a pH-dependent polymer, wherein the sustained release granule is coated with the pH-dependent polymer, and the opioid receptor antagonist is selected from the group consisting of Nalmefene, Naltrexone, or a salt thereof.

Abstract: An object of the present invention is to obtain a capsule for treating ulcerative colitis which, when a capsule containing indigo is orally administered, acts more effectively than conventional ones and has less side effects of hepatotoxicity by not easily disintegrating in the stomach and small intestine but only in the large intestine. The present invention relates to a capsule for treating ulcerative colitis which disintegrates locally in the large intestine, comprising a drug-containing content, a protective layer coating the content and a film formed outside the protective layer, which are arranged concentrically, wherein the content is a content in which indigo, which is a drug for treating ulcerative colitis, is dispersed or dissolved, and the film is locally disintegrated in the large intestine.

Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.

Abstract: Compositions, articles, and methods for targeted drug delivery, such as thermoresponsive hydrogel polymers, are generally provided. In one aspect, the compositions and articles comprise a thermoresponsive hydrogel polymer comprising a releasable therapeutic agent. In some cases, the compositions described herein have advantageous combinations of properties including mechanical strength, biocompatibility, tunable charge densities, thermal responsiveness, drug loading, and/or configurations for targeted drug delivery. In one embodiment, the composition comprises a solution comprising a thermoresponsive polymer including one or more ligands attached to the polymer, wherein the solution is configured to undergo a sol-to-gel transition under physiological conditions. In another embodiment, the composition comprises a plurality of nanoparticles e.g., associated with the thermoresponsive polymer. In yet another embodiment, the composition comprises a therapeutic agent e.g.

Abstract: A microdevice containing a plurality of nanowires on a biocompatible surface, and methods of making and using the same are provided. Aspects of the present disclosure include forming a plurality of microdevices on a substrate where each microdevice includes a plurality of nanowires. The nanowires may be loaded with an active agent by disposing the active agent onto the surface of the nanowires. Also provided herein are kits that include the subject microdevices.

Abstract: The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide, terpene-based resin, rosin-based resin, styrene-isoprene-styrene block copolymer, and liquid paraffin, a mass ratio of a content of the terpene-based resin to a content of the rosin-based resin ((content of the terpene-based resin)/(content of the rosin-based resin)) in the adhesive agent layer is 0.45 to 1.3, and a mass ratio of a content of the styrene-isoprene-styrene block copolymer to a content of the liquid paraffin ((content of the styrene-isoprene-styrene block copolymer)/(content of the liquid paraffin)) in the adhesive agent layer is 0.45 to 1.2.

Abstract: The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide and aluminum hydroxide, a content of nonylic acid vanillylamide in the adhesive agent layer is 0.01 to 0.025% by mass based on a total mass of the adhesive agent layer, a content of aluminum hydroxide in the adhesive agent layer is 0.55 to 1.5% by mass based on the total mass of the adhesive agent layer, and a mass ratio of the content of nonylic acid vanillylamide to the content of aluminum hydroxide ((content of nonylic acid vanillylamide):(content of aluminum hydroxide)) in the adhesive agent layer is 1:27 to 1:150.

Abstract: A method of immunological evaluation includes cleaning a skin surface area of a patient. A controlled amount of heat is then applied to the skin surface area. The controlled amount of heat is removed after the skin surface area reaches a predetermined temperature. An amount of antigen is deposited onto the skin surface area and incubated for a predetermined amount of time on the skin surface area. The antigen is removed from the skin surface area and an immunological response at the skin surface area is evaluated. Apparatus for administering heat and memorializing the evaluation are also disclosed.